Express Scripts is suing the Federal Trade Commission (FTC) over a July 2024 report it claims is misleading and harmful to the pharmacy benefit manager (PBM) industry.

What they found: The PBMs marked up prices for specialty generic drugs by hundreds and sometimes thousands of percent over their estimated acquisition costs from 2017 and 2022, per the FTC report.

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...

PBMs’ practices are largely to blame for this increase in insulin prices, the complaint alleges. CVS Caremark, Express Scripts and Optum Rx administer about 80% of all prescriptions in the U.S ...

The FTC’s First Interim Report found that pharmacies affiliated with the three largest PBMs in the United States received 68 percent of all revenue for dispensing specialty drugs in 2023 (up ...

The FTC should produce a full report that provides empirical analysis of PBMs and the healthcare market. Policymakers at every level depend on it to sort through the noise of politics to make ...

Opinion: Miami attorney Gregg Goldfarb says wielding antitrust, fraud, and nuisance claims can help attorneys score wins in ...

In a Kansas City Star guest commentary (6/25/25 page 14A), Jamie Corley, executive director of the nonprofit Prescription Benefits Matter, stated that pharmacy benefit managers help Missourians afford ...

The FTC report has a “clear ideological bias” and makes misleading claims about PBMs that could lead to policies that would inflate drug costs, Cigna Chief Legal Officer Andrea Nelson said in ...

The FTC report was the product of a PBM investigation that the FTC announced in 2022. Investigators ended up looking at both PBMs and prescription drug group purchasing organizations.

FTC's July 2024 report makes unsubstantiated, false and biased claims about the PBM industry; fails to take into account the value that PBMs deliver to consumers and patients. ST. LOUIS, Sept. 17 ...